These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 9065922)

  • 21. [Prospective randomized trial on the efficacy of adjuvant endocrine therapy for ER-positive breast cancer patients after radical mastectomy].
    Jiang Z; Song S; Liu X
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):420-2. PubMed ID: 11810777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
    Lash TL; Gurwitz JH; Silliman RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-The role of p53.
    Rahko E; Blanco G; Bloigu R; Soini Y; Talvensaari-Mattila A; Jukkola A
    Breast; 2006 Feb; 15(1):69-75. PubMed ID: 16005229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fulvestrant: a new agent in endocrine treatment for breast cancer].
    Juretić A; Sarić N; Bisof V; Basić-Koretić M
    Lijec Vjesn; 2006; 128(1-2):31-6. PubMed ID: 16640225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reliability of estrogen receptors in predicting response to antiestrogens.
    Valavaara R
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):14-8. PubMed ID: 9165501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of ovarian ablation in the management of breast cancer.
    Wirk B
    Breast J; 2005; 11(6):416-24. PubMed ID: 16297086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pure antiestrogens as a new therapy for breast cancer.
    England GM; Jordan VC
    Oncol Res; 1997; 9(8):397-402. PubMed ID: 9436192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
    Ward JH
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Nabholtz JM
    Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen ("Nolvadex"): a review.
    Clemons M; Danson S; Howell A
    Cancer Treat Rev; 2002 Aug; 28(4):165-80. PubMed ID: 12363457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tamoxifen's impact on the management of breast cancer: the oncologist's perspective.
    Glick JH; Aviles VM; Wallmark J
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):49-54. PubMed ID: 9065928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Status of antiestrogen breast cancer prevention trials.
    Powles TJ
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tamoxifen in early breast cancer.
    Bryce CJ
    Lancet; 1998 Aug; 352(9125):403. PubMed ID: 9717952
    [No Abstract]   [Full Text] [Related]  

  • 37. Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.
    Jordan VC
    Breast Cancer Res Treat; 1995; 36(3):267-85. PubMed ID: 8573710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of tamoxifen in the treatment and prevention of breast cancer.
    Jordan VC
    Curr Probl Cancer; 1992; 16(3):129-76. PubMed ID: 1582240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamoxifen--an update on current data and where it can now be used.
    Wickerham L
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S7-12; discussion S33-5. PubMed ID: 12353826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen in the treatment of breast cancer.
    Legha SS
    Ann Intern Med; 1988 Aug; 109(3):219-28. PubMed ID: 3291659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.